Drugs / GD2 CAR T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05990751 | Apr 2024 → Dec 2026 expected | neuroblastoma | University College, London | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05544526 | Aug 2023 → Dec 2025 overdue | diffuse midline glioma, H3 K27M-mutant | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT04196413 | Jun 2020 → Jul 2028 expected | brain stem glioma, spinal cord glioma | Stanford University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05544526 ↗ |
| Modality | Cell therapy | “Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor” NCT04196413 ↗ |
| Route | Intravenous | “Intravenously, after conditioning lymphodepletion chemotherapy regimen with cyclophosphamide and fludarabine” NCT04196413 ↗ |